Moving one step further, Di Tacchio et al. [141] employed a combination of anti-angiogenics (blocking VEGF and Ang-2) plus an immune checkpoint inhibitor (PD-1) in an orthotopic glioblastoma model. This evidence concerns the gene VEGFA and glioblastoma.